Risk of mucocutaneous toxicities in patients with solid tumors treated with lapatinib: A systematic review and meta-analysis

Current Medical Research and Opinion

Volumn 31, Issue 5, 2015, Pages 975-986

  Abdel Rahman, Omar ^a   Fouad, Mona ^a  

^a AIN SHAMS UNIVERSITY   (Egypt)

Author keywords

Lapatinib; Meta analysis; Skin rash; Stomatitis

Indexed keywords

LAPATINIB; ANTINEOPLASTIC AGENT; QUINAZOLINE DERIVATIVE;

ALOPECIA; BREAST CANCER; CANCER PATIENT; DRUG ERUPTION; HAND FOOT SYNDROME; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; INCIDENCE; KIDNEY CARCINOMA; META ANALYSIS; MONOTHERAPY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; RISK FACTOR; SKIN PRURITUS; SKIN TOXICITY; SOLID TUMOR; STOMATITIS; SYSTEMATIC REVIEW; UTERINE CERVIX CARCINOMA; CHEMICALLY INDUCED; HAND-FOOT SYNDROME; NEOPLASMS; PRURITUS; RISK;

ALOPECIA; ANTINEOPLASTIC AGENTS; HAND-FOOT SYNDROME; HUMANS; NEOPLASMS; PRURITUS; QUINAZOLINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK;

EID: 84928191646     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2015.1020367     Document Type: Review

References (44)

1. Paul B, Trovato JA, Thompson J. Lapatinib: a dual tyrosine kinase inhibitor for metastatic breast cancer. Am J Health Syst Pharm 2008;65:1703-10
2. Untch M, Lück HJ. Lapatinib-member of a new generation of ErbB-targeting drugs. Breast Care (Basel) 2010;5:8-12
3. Abdel-Rahman O. Systemic therapy for hepatocellular carcinoma (HCC): from bench to bedside. J Egypt Natl Canc Inst 2013;25:165-71
4. Abdel-Rahman O, Abdelwahab M, Shaker M, et al. Sorafenib versus capecitabine in the management of advanced hepatocellular carcinoma. Med Oncol 2013;30:655
5. Tykerb (lapatinib) FDA prescribing information. Available at: http://www. accessdata.fda.gov/drugsatfda-docs/label/2010/022059s007lbl.pdf [Last accessed 1 December 2013]
6. Abdel-Rahman O, Elsayed Z. Combination trans arterial chemoembolization (TACE) plus sorafenib for the management of unresectable hepatocellular carcinoma: a systematic review of the literature. Dig Dis Sci 2013;58:3389-96
7. Abdel-Rahman O, Fouad M. Does the use of lapatinib increase the risk of fatigue and hepatic toxicities in patients with solid tumors? A critical literature review and meta analysis. Expert Opinion Drug Saf 2014;13:999-1008
8. Azim Jr. HA, Agbor-Tarh D, Bradbury I, et al. Pattern of rash, diarrhea, and hepatic toxicities secondary to lapatinib and their association with age and response to neoadjuvant therapy: analysis from the NeoALTTO trial. J Clin Oncol 2013;31:4504-11
9. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement. J Clin Epidemiol 2009;62:1006-12
10. National cancer institute. Common toxicity criteria. Available at: http:// ctep.cancer.gov/protocoldevelopment/electronic-applications/docs/ctcaev3. pdf [Last accessed 1 December 2014]
11. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60
12. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-88
13. Robidoux A, Tang G, Rastogi P. Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial. Lancet Oncol 2013;14:1183-92
14. Guarneri V, Frassoldati A, Bottini A. Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase II CHER-LOB study. J Clin Oncol 2012;30:1989-95
15. Untch M, Loibl S, Bischoff J. Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial. Lancet Oncol 2012;13:135-44
16. DeCensi A, Puntoni M, Pruneri G. Lapatinib activity in premalignant lesions and HER-2-positive cancer of the breast in a randomized, placebo-controlled presurgical trial. Cancer Prev Res (Phila) 2011;4:1181-9
17. Ravaud A, Hawkins R, Gardner JP. Lapatinib versus hormone therapy in patients with advanced renal cell carcinoma: a randomized phase III clinical trial. J Clin Oncol 2008;26:2285-91
18. Goss PE, Smith IE, O'shaughnessy J. Adjuvant lapatinib for women with earlystage HER2-positive breast cancer: a randomised, controlled, phase 3 trial. Lancet Oncol 2013;14:88-96
19. Baselga J, Bradbury I, Eidtmann H. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet 2012;379:633-40
20. Johnston SR, Gómez H, Stemmer SM. A randomized and open-label trial evaluating the addition of pazopanib to lapatinib as first-line therapy in patients with HER2-positive advanced breast cancer. Breast Cancer Res Treat 2013;137:755-66
21. Verma S, Miles D, Gianni L, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 2012;367:1783-91
22. Cristofanilli M, Johnston SR, Manikhas A, et al. A randomized phase II study of lapatinibpazopanib versus lapatinib in patients with HER2 inflammatory breast cancer. Breast Cancer Res Treat 2013;137:471-82
23. Martin M, Bonneterre J, Geyer Jr CE, et al. A phase two randomised trial of neratinib monotherapy versus lapatinib plus capecitabine combination therapy in patients with HER2 advanced breast cancer. Eur J Cancer 2013; 49:3763-72
24. Lin NU, Eierman W, Greil R. Randomized phase II study of lapatinib plus capecitabine or lapatinib plus topotecan for patients with HER2-positive breast cancer brain metastases. J Neurooncol 2011;105:613-20
25. Schwarzberg LS, Franco SX. Lapatinib plus letrozole as first-line therapy for HER-2 hormone receptor-positive metastatic breast cancer. Oncologist 2010;15:122-9
26. Johnston S, Pippen J, Pivot X. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol 2009;27:5538-46
27. Di Leo A, Gomez HL, Aziz Z, et al. Phase III, doubleblind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer. J Clin Oncol 2008;26:5544-52
28. Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006;355:2733-43
29. Del Campo JM, Hitt R, Sebastian P. Effects of lapatinib monotherapy: results of a randomised phase II study in therapy-naive patients with locally advanced squamous cell carcinoma of the head and neck. Br J Cancer 2011;105:618-27
30. Monk BJ, Mas lopez L, Zarba JJ. Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer. J Clin Oncol 2010;28:3562-9
31. Harrington K, Berrier A, Robinson M, et al. Randomised phase II study of oral lapatinib combined with chemoradiotherapy in patients with advanced squamous cell carcinoma of the head and neck: rationale for future randomised trials in human papilloma virus-negative disease. Eur J Cancer 2013; 49:1609-18
32. Hicks DG, Whitney-Miller CL. The evolving role of HER2 evaluation for diagnosis and clinical decision making for breast and gastric adenocarcinoma. Biotech Histochem 2013;88:121-31
33. Cui H, Cheng Y, Piao SZ, et al. Correlation between HER-2/neu(erbB-2) expression level and therapeutic effect of combination treatment with HERCEPTIN and chemotherapeutic agents in gastric cancer cell lines. Cancer Cell Int 2014;14:10
34. Konecny GE, Pegram MD, Venkatesan N, et al. Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab treated breast cancer cells. Cancer Res 2006;66:1630-9
35. Johnson BE, Kabbinavar F, Fehrenbacher L, et al. ATLAS: randomized, double-blind, placebo-controlled, phase IIIB trial comparing bevacizumab therapy with or without erlotinib, after completion of chemotherapy, with bevacizumab for firstline treatment of advanced non-small-cell lung cancer. J Clin Oncol 2013;31:3926-34
36. Abdel-Rahman O, Abdelwahab M, Shaker M, et al. Sorafenib for Egyptian patients with advanced hepatocellular carcinoma; single center experience. J Egyptian Nat Cancer Inst 2014;26:9-13. doi: 10.1016/j.jnci.2013.08.003
37. Abdel-Rahman O, Fouad M. Sorafenib-based combination as a first line treatment for advanced hepatocellular carcinoma; a systematic review of the literature. Crit Rev Oncol Hematol 2014;91:1-8 doi: 10.1016/j.critrevonc. 2013.12.013
38. Chan A, Tan EH. How well does the MESTT correlate with CTCAE scale for the grading of dermatological toxicities associated with oral tyrosine kinase inhibitors? Support Care Canc 2011;19:1667-74
39. Potthoff K, Hofheinz R, Hassel JC, et al. Interdisciplinary management of EGFR-inhibitor-induced skin reactions: a German expert opinion. Ann Oncol 2011;22:524-35
40. Chow LW, Xu B, Gupta S, et al. Combination neratinib (HKI-272) and paclitaxel therapy in patients with HER2-positive metastatic breast cancer. Br J Canc 2013;108:1985-93
41. Douillard JY, Ostoros G, Cobo M, et al. First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study. Br J Canc 2013;110:55-62
42. Newman M, Gerami P, Guitart J, et al. Histological differentiation of skin toxicity between cetuximab, erlotinib and panitumumab (single ErbB1) and lapatinib (dual ErbB1/2) epidermal growth factor receptor inhibitors. J Clin Oncol (Meeting Abstracts) 2009;27:e20617
43. Nardone B, Kaklamani VG, Nicholson KM, et al. Histopathologic and immunohistochemical findings of skin rash to HER1 and HER1/2 inhibitors during anticancer therapy. J Clin Oncol (Meeting Abstracts) 2010; 28(Suppl):2581
44. Ensslin CJ, Rosen AC, Wu S, Lacouture ME. Pruritus in patients treated with targeted cancer therapies: systematic review and meta-analysis. J Am Acad Dermatol 2013;69:708-20